Agenus Inc. (NASDAQ:AGEN) Shares Sold by Putnam Investments LLC

Putnam Investments LLC trimmed its stake in shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) by 1.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 523,516 shares of the biotechnology company’s stock after selling 9,534 shares during the quarter. Putnam Investments LLC owned about 0.17% of Agenus worth $1,073,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in AGEN. Point72 Asset Management L.P. raised its position in shares of Agenus by 943.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 8,372,200 shares of the biotechnology company’s stock worth $17,163,000 after purchasing an additional 7,569,600 shares during the period. State Street Corp increased its position in Agenus by 30.9% in the 2nd quarter. State Street Corp now owns 23,243,261 shares of the biotechnology company’s stock valued at $45,092,000 after acquiring an additional 5,484,637 shares during the period. Renaissance Technologies LLC increased its position in Agenus by 77.1% in the 1st quarter. Renaissance Technologies LLC now owns 4,922,715 shares of the biotechnology company’s stock valued at $12,110,000 after acquiring an additional 2,143,000 shares during the period. Sofinnova Investments Inc. increased its position in Agenus by 155.8% in the 3rd quarter. Sofinnova Investments Inc. now owns 2,437,465 shares of the biotechnology company’s stock valued at $4,997,000 after acquiring an additional 1,484,723 shares during the period. Finally, Prudential Financial Inc. increased its position in Agenus by 7,745.3% in the 3rd quarter. Prudential Financial Inc. now owns 1,387,835 shares of the biotechnology company’s stock valued at $2,846,000 after acquiring an additional 1,370,145 shares during the period. 53.81% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on AGEN. EF Hutton Acquisition Co. I began coverage on Agenus in a research report on Thursday, December 22nd. They issued a “buy” rating and a $8.30 target price on the stock. StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a research report on Monday, November 14th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Agenus in a research report on Tuesday, February 28th. One research analyst has rated the stock with a sell rating and three have issued a buy rating to the company. Based on data from MarketBeat, Agenus presently has a consensus rating of “Moderate Buy” and an average price target of $7.10.

Agenus Stock Performance

Shares of AGEN stock opened at $1.71 on Tuesday. Agenus Inc. has a 1 year low of $1.25 and a 1 year high of $3.37. The stock has a market cap of $521.23 million, a PE ratio of -2.11 and a beta of 1.50. The business’s fifty day moving average is $2.32 and its 200-day moving average is $2.46.

Agenus Company Profile

(Get Rating)

Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.